Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
Results showed VK0214 to be safe and well-tolerated following once-daily dosing over the 28-day study period.On Wednesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released data from the Phase 1b trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRβ), in patients with X-linked adrenoleukodystrophy (X-ALD).
週三，viking therapeutics公司（納斯達克:VKTX）公佈了VK0214的第一期研究數據，這是一種新型小分子激動劑，作用於甲狀腺激素受體β（TRβ），用於治療X連鎖腎上腺白質腦病（X-ALD）患者。
X-linked adrenoleukodystrophy is a genetic disorder that mainly affects the nervous system and the adrenal glands, which are located on top of each kidney.
X連鎖腎上腺白質腦病是一種主要影響神經系統和位於每個腎臟上方的腎上腺的遺傳性疾病。
Also Read: Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know.
此外閱讀：viking therapeutics股價飆升，公司推進減重藥物進入晚期試驗階段：投資者需要了解的事情。
Results showed VK0214 to be safe and well-tolerated following once-daily dosing over the 28-day study period.
研究結果顯示，在28天的研究期內，VK0214每日一次給藥後，患者安全耐受良好。
In addition, plasma levels of very long-chain fatty acids (VLCFAs) and other lipids were significantly reduced compared to placebo.
此外，與安慰劑相比，血漿中非常長鏈脂肪酸（VLCFAs）和其他脂質水平顯著降低。
VLCFAs are considered biomarkers of disease in patients with X-ALD. Treatment with VK0214 resulted in significant reductions in mean VLCFA levels at both doses evaluated, 20 mg/day and 40 mg/day, compared to placebo.
VLCFAs被認爲是X-ALD患者疾病的生物標誌物。VK0214治療導致兩個劑量組，20毫克/天和40毫克/天，在平均VLCFA水平上顯著降低，而安慰劑組則未見明顯變化。
Cohorts receiving VK0214 demonstrated reductions in mean plasma levels of the 26 carbon lysophosphatidyl choline (C26:0-LPC) derivative, a key diagnostic marker.
接受VK0214的隊列，C26:0-LPC的均值血漿水平減少，這是一種關鍵的診斷標誌物。40毫克組觀察到14.8%的降低（p=0.0105），而20毫克組降低了8.4%（p=0.0427）。除了VLCFA的變化，接受VK0214的受試者表現出其他血漿脂質的降低。
A 14.8% reduction was observed in the 40 mg cohort (p=0.0105) and a reduction of 8.4% in the 20 mg cohort (p=0.0427). In addition to VLCFA changes, subjects who received VK0214 demonstrated reductions in other plasma lipids.
收到VK0214的受試者除了VLCFA的變化外，還顯示出其他血漿脂質的降低。
Mean reductions relative to baseline and placebo were observed for low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and lipoprotein (a) [Lp(a)] following 28 days of treatment.
在治療28天后觀察到相對於基線和安慰劑的低密度脂蛋白膽固醇（LDL-C）、載脂蛋白b（ApoB）和脂蛋白（a）[Lp(a)]的平均減少。
Treatment-emergent adverse events were reported as mild to moderate. Gastrointestinal adverse events were slightly higher among placebo subjects (33%) compared with VK0214-treated subjects (11%).
治療相關的不良事件報告爲輕微至中度。與安慰劑組（33%）相比，VK0214處理組（11%）的胃腸道不良事件略高。
William Blair highlights that the positive progress of VK0214 provides investors with additional opportunities beyond Viking's existing programs, including the subcutaneous and oral formulations of VK2735 for obesity, VK2809 for metabolic-dysfunction-associated steatohepatitis (MASH), and its preclinical amylin program, which is expected to enter clinical trials next year.
William Blair強調VK0214積極進展爲投資者提供了維京療法現有項目以外的額外機會，包括面向肥胖症的VK2735的皮下和口服制劑、面向代謝功能紊亂相關脂肪肝（MASH）的VK2809，以及預計明年將進入臨床試驗的臨床前肽類項目。
Since the analyst believes most investors have yet to factor in the potential revenue from VK0214, its continued successful development could offer an upside to current projections. Moreover, the focus on treating an orphan disease broadens Viking's potential revenue streams by expanding from the larger obesity and MASH markets into the rare disease space.
由於分析師認爲大多數投資者尚未考慮到來自VK0214的潛在營業收入，該療法的持續成功發展可能對當前的預測產生積極影響。此外，專注治療孤兒疾病擴展了維京療法的潛在營收渠道，從較大的肥胖和MASH市場擴展到罕見疾病領域。
Price Action: VKTX stock is down 2.67% at $64.90 at the last check on Wednesday.
價格走勢：VKTX股價在週三最新查詢時下跌2.67%，報64.90美元。
- Honda Recalls 1.7M Vehicles Over Steering Gearbox Defect.
- 本田因轉向齒輪箱缺陷召回170萬輛車。
譯文內容由第三人軟體翻譯。
